|
|
|
|
|
|
|
||
Evidence from Experiments with Neutral and Quaternary Flecainide Analogues
Address correspondence to Robert S. Kass, Department of Pharmacology, College of Physicians and Surgeons of Columbia University, 630 W. 168th St., New York, NY 10032. Fax: (212) 342-2703; E-mail: rsk20{at}columbia.edu
Flecainide (pKa 9.3, 99% charged at pH 7.4) and lidocaine (pKa 7.6–8.0, 
50% neutral at pH 7.4) have similar structures but markedly different effects on Na+ channel activity. Both drugs cause well-characterized use-dependent block (UDB) of Na+ channels due to stabilization of the inactivated state, but flecainide requires that channels first open before block develops, whereas lidocaine is believed to bind directly to the inactivated state. To test whether the charge on flecainide might determine its state specificity of Na+ channel blockade, we developed two flecainide analogues, NU-FL (pKa 6.4), that is 90% neutral at pH 7.4, and a quaternary flecainide analogue, QX-FL, that is fully charged at physiological pH. We examined the effects of flecainide, NU-FL, QX-FL, and lidocaine on human cardiac Na+ channels expressed in human embryonic kidney (HEK) 293 cells. At physiological pH, NU-FL, like lidocaine but not flecainide, interacts preferentially with inactivated channels without prerequisite channel opening, and causes minimal UDB. We find that UDB develops predominantly by the charged form of flecainide as evidenced by investigation of QX-FL at physiological pH and NU-FL investigated over a more acidic pH range where its charged fraction is increased. QX-FL is a potent blocker of channels when applied from inside the cell, but acts very weakly with external application. UDB by QX-FL, like flecainide, develops only after channels open. Once blocked, channels recover very slowly from QX-FL block, apparently without requisite channel opening. Our data strongly suggest that it is the difference in degree of ionization (pKa) between lidocaine and flecainide, rather than gross structural features, that determines distinction in block of cardiac Na+ channels. The data also suggest that the two drugs share a common receptor but, consistent with the modulated receptor hypothesis, reach this receptor by distinct routes dictated by the degree of ionization of the drug molecules.
Key Words: electrophysiology • local anesthetics • flecainide • arrhythmia • pharmacology
CiteULike 
Complore 
Connotea 
Del.icio.us 
Digg 
Reddit 
Technorati What's this?
This article has been cited by other articles:
|
|
 |
|
  C. A. Ahern, A. L. Eastwood, D. A. Dougherty, and R. Horn Electrostatic Contributions of Aromatic Residues in the Local Anesthetic Receptor of Voltage-Gated Sodium Channels Circ. Res., January 4, 2008; 102(1): 86 - 94. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. M. McNulty, G. B. Edgerton, R. D. Shah, D. A. Hanck, H. A. Fozzard, and G. M. Lipkind Charge at the lidocaine binding site residue Phe-1759 affects permeation in human cardiac voltage-gated sodium channels J. Physiol., June 1, 2007; 581(2): 741 - 755. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 C. E. Clancy, Z. I. Zhu, and Y. Rudy Pharmacogenetics and anti-arrhythmic drug therapy: a theoretical investigation Am J Physiol Heart Circ Physiol, January 1, 2007; 292(1): H66 - H75. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
Y. Zhu, J. W. Kyle, and P. J. Lee Flecainide sensitivity of a Na channel long QT mutation shows an open-channel blocking mechanism for use-dependent block Am J Physiol Heart Circ Physiol, July 1, 2006; 291(1): H29 - H37. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
K. Fukuda, S. S. Davies, T. Nakajima, B.-H. Ong, S. Kupershmidt, J. Fessel, V. Amarnath, M. E. Anderson, P. A. Boyden, P. C. Viswanathan, et al. Oxidative Mediated Lipid Peroxidation Recapitulates Proarrhythmic Effects on Cardiac Sodium Channels Circ. Res., December 9, 2005; 97(12): 1262 - 1269. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 G. M. Lipkind and H. A. Fozzard Molecular Modeling of Local Anesthetic Drug Binding by Voltage-Gated Sodium Channels Mol. Pharmacol., December 1, 2005; 68(6): 1611 - 1622. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
E. Ramos and M. E O'Leary State-dependent trapping of flecainide in the cardiac sodium channel J. Physiol., October 1, 2004; 560(1): 37 - 49. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 H. K. Motoike, H. Liu, I. W. Glaaser, A.-S. Yang, M. Tateyama, and R. S. Kass The Na+ Channel Inactivation Gate Is a Molecular Complex: A Novel Role of the COOH-terminal Domain J. Gen. Physiol., January 26, 2004; 123(2): 155 - 165. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J.-F. Desaphy, A. D. E. Luca, M. P. Didonna, A. L. George Jr, and D. C. Camerino Different flecainide sensitivity of hNav1.4 channels and myotonic mutants explained by state-dependent block J. Physiol., January 15, 2004; 554(2): 321 - 334. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. De Luca, S. Talon, M. De Bellis, J.-F. Desaphy, G. Lentini, F. Corbo, A. Scilimati, C. Franchini, V. Tortorella, and D. C. Camerino Optimal Requirements for High Affinity and Use-Dependent Block of Skeletal Muscle Sodium Channel by N-Benzyl Analogs of Tocainide-Like Compounds Mol. Pharmacol., October 1, 2003; 64(4): 932 - 945. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
G. K. Wang, C. Russell, and S.-Y. Wang State-dependent Block of Wild-type and Inactivation-deficient Na+ Channels by Flecainide J. Gen. Physiol., August 25, 2003; 122(3): 365 - 374. [Abstract] [Full Text] [PDF]
|
|
|
|
